Azole resistance in Candida

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 4, 1997, Pages 261-280

  Denning, D W ^a,b,c   Baily, G G ^a,d   Hood, S V ^a  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE;

CANDIDIASIS; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MONITORING; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0030909476     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01695630     Document Type: Review

References (163)

1. British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection: Management of deep Candida infection in the surgical and intensive care unit patient. Intensive Care Medicine 1994, 20: 522-528.
2. Rogers TE, Galgiani JN: Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrobial Agents and Chemotherapy 1986, 30: 418-422.
3. Fisher MA, Shen SH, Haddad J, Tarry WF: Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida albicans, Candida glabrata and Candida krusei. Antimicrobial Agents and Chemotherapy 1989, 33: 1443-1446.
4. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW: High prevalence of antifungal resistance in Candida spp. from patients with AIDS. Journal of Antimicrobial Chemotherapy 1994, 34: 659-668.
5. Johnson EM, Davey KG, Szekely A, Warnock DW: Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. Journal of Antimicrobial Chemotherapy 1995, 36: 787-794.
6. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD and the NIAID Mycoses Study Group and the Candidemia Study Group: Antifungal susceptibility testing of isolates from a randomized, multicentre trial of fluconazole versus amphotericin B as treatment of non neutropenic patients with candidaemia. Antimicrobial Agents and Chemotherapy 1995, 39: 40-44.
7. Scholer HJ, Polak A: Resistance to systemic antifungal agents. In: Bryan LE (ed): Antimicrobial drug resistance. Academic Press, Orlando, 1984, p. 393-460.
8. Ahearn DG, McGlohn MS: In vitro susceptibilities of sucrose negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole and ketoconazole. Journal of Clinical Microbiology 1984, 19: 412-416.
9. Merz WG, Khazan U, Jabra-Rizk MA, Wu LC, Osterhout GJ, Lehmann PF: Strain delineation and epidemiology of Candida (Clavispora) lusitaniae. Journal of Clinical Microbiology 1992, 30: 449-454.
10. Rosenblatt HM, Byrne W, Ament ME, Graybill J, Stiehm ER: Successful treatment of chronic mucocutaneous candidiasis with ketoconazole. Journal of Pediatrics 1980, 97: 657-660.
11. Horsburgh CR, Kirkpatrick CH: Long term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with 21 patients. American Journal of Medicine 1983, 74: 23-29.
12. Warnock DW, Johnson EM, Richardson MD, Vickers CFH: Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet 1983, ii: 642-643.
13. Fox R, Neal KR, Leen CLS, Ellis ME, Mandal BK: Fluconazole resistant Candida in AIDS. Journal of Infection 1991, 22: 201-202.
14. Willcocks L, Leen CLS, Brettle RP, Urquhart D, Russell TB, Milne LJR: Fluconazole resistance in AIDS patients. Journal of Antimicrobial Chemotherapy 1991, 28: 937-939.
15. Kitchen VS, Savage M, Harris JRW: Candida albicans resistance in AIDS. Journal of Infection 1991, 22: 204-205.
16. Smith D, Boag F, Midgley J, Gazzard B: Fluconazole resistant Candida in AIDS. Journal of Infection 1991, 23: 345-346.
17. Odds FC: Resistance of yeasts to azole-derivative antifungals. Journal of Antimicrobial Chemotherapy 1993, 31: 463-471.
18. Ng TTC, Denning DW: Fluconazole resistance in Candida in patients with AIDS - a therapeutic approach. Journal of Infection 1993, 26: 117-125.
19. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN: Antifungal susceptibility testing. Clinical Microbiology Reviews 1993, 6: 367-381.
20. Ghannoum MA, Rex JH, Galgiani JN: Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. Journal of Clinical Microbiology 1996, 34: 489-495.
21. Denning DW, Stevens DA: Editorial. New drugs for systemic fungal infections. Greater choice and more difficult clinical decisions. British Medical Journal 1989, 299: 407-408.
22. Troke PF, Pye GW: Antifungal susceptibility testing. A manual of methods in development (FLU-92-010MM). Pfizer Central Research, Sandwich, UK, 1992.
23. Regli P, Blancard A, Goudard M, Moulin-Traffort J, Sarzier JM, Quilici M: Évaluation de la sensibilité in vitro au fluconazole de différentes espèces de levures rencontrées en pathologie. Pathologie Biologique 1992, 40: 500-506.
24. Blancard A, Moulin-Traffort J, Regli P, Sarzier JM, Quilici M: Apport du laboratoire dans la surveillance du traitement antifongique par le fluconazole des candidoses chez les immunodeprimes. Pathologie Biologique 1991, 39: 534-538.
25. Sandven P, Bjorneklett A, Maeland A and the Norwegian Yeast Study Group: Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrobial Agents and Chemotherapy 1993, 37: 2443-2448.
26. Ruhnke M, Eigler A, Engelmann E, Geiseler B, Trautmann M: Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 1994, 22: 132-136.
27. Imbert-Bernard C, Valentin A, Reynes J, Mallie M, Bastide JM: Relationship between fluconazole sensitivity of Candida albicans isolates from HIV positive patients and serotype adherence and CD4+ lymphocyte count. European Journal of Clinical Microbiology & Infectious Diseases 1994, 13: 711-716.
28. Pfaller MA, Burmeister L, Bartlett MS, Rinaldi MG: Multicentre evaluation of four methods of yeast inoculum preparation. Journal of Clinical Microbiology 1988, 26: 1437-1441.
29. Pfaller MA, Rinaldi MG, Galgiani JN, Bartlett MS, Body BA, Espinel-Ingroff A, Fromtling RA, Hall GS, Hughes CE, Odds FC, Sugar AM: Collaborative investigation of variables in antifungal susceptibility testing of yeasts. Antimicrobial Agents and Chemotherapy 1990, 34: 1648-1654.
30. Odds FC, Milne LJR, Gentles JC, Ball HE: The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. Journal of Antimicrobial Chemotherapy 1980, 6: 97-104.
31. Calhoun DL, Roberts GD, Galgiani JN, Bennett JE, Feingold DS, Jorgensen J, Kobayashi GS, Shadomy S: Resuits of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. Journal of Clinical Microbiology 1986, 23: 298-301.
32. Galgiani JN: Antifungal susceptibility tests. Antimicrobial Agents and Chemotherapy 1987, 31: 1867-1870.
33. Pfaller MA, Dupont B, Kobayashi GS, Muller J, Rinaldi MG, Espinel-Ingroff A, Shadomy S, Troke PF, Walsh TJ, Warnock DW: Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrobial Agents and Chemotherapy 1992, 36: 1805-1809.
34. Shawar R, Paetznick V, Witte Z, Ensign LG, Anaissie E, LaRocco M: Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans. Journal of Clinical Microbiology 1992, 30: 1976-1981.
35. Espinel-Ingroff A, Kerkering TM, Goldson PR, Shadomy S: Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. Journal of Clinical Microbiology 1991, 29: 1089-1094.
36. Espinel-Ingroff A, Kish Jr CW, Kerkering TM, Fromtling RA, Bartizal KF, Bartlett MS, Body BA, Frey C, Hall G, Roberts GD, Nolte FB, Odds FC, Rinaldi MG, Sugar AM, Villareal K: Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. Journal of Clinical Microbiology 1992, 30: 3138-3145.
37. Sewell DL, Pfaller MA, Barry AL: Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. Journal of Clinical Microbiology 1994, 32: 2099-2102.
38. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed Standard M27-P NCCLS, Villanova, PA, 1992.
39. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard. NCCLS document M27-T. NCCLS, Villanova, PA, 1995.
40. Anaissie E, Paetznick V, Bodey GP: Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature and time of reading. Antimicrobial Agents and Chemotherapy 1991, 35: 1641-1646.
41. Fan-Havard P, Capano D, Smith SM, Mangia A, Eng RHJ: Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrobial Agents and Chemotherapy 1991, 35: 2302-2305.
42. Pfaller MA, Buschelman B, Bale MJ, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG: Multicenter comparison of colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. Diagnostic Microbiology and Infectious Diseases 1994, 19: 9-13.
43. Rodriguez-Tudela JL, Martinez-Suarez JV: Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrobial Agents and Chemotherapy 1994, 38: 45-48.
44. Chavanet P, Lopez J, Grappin M, Bonnin A, Duong M, Waldner A, Buisson M, Camerlynck P, Portier H: Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994, 8: 945-950.
45. Quereda C, Polanco AM, Giner C, Sánchez-Sousa A, Pereira E, Navas E, Fortún J, Guerrero A, Baquero F: Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1996, 15: 30-37.
46. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M: Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. Journal of Clinical Microbiology 1994, 32: 2092-2098.
47. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C: Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. Journal of Antimicrobial Chemotherapy 1995, 35: 103-114.
48. Polanco AM, Rodriguez-Tudela JL, Baquero F, Sanchez-Sousa A, Martinez-Suarez JV: Improved method of determining the susceptibility of Candida albicans to fluconazole. Journal of Antimicrobial Chemotherapy 1995, 35: 155-159.
49. Fournier C, Gaspar A, Boillot F, Villard J: Evaluation of a broth microdilution antifungal susceptibility test with a pH indicator: comparison with the broth macrodilution procedure. Journal of Antimicrobial Chemotherapy 1995, 35: 373-380.
50. Cartledge JD, Midgley J, Gazzard BG: Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis. Journal of Antimicrobial Chemotherapy 1996, 37: 275-283.
51. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR: Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 1993, 37: 2449-2453.
52. Espinel-Ingroff A: E test for antifungal susceptibility testing of yeasts. Diagnostic Microbiology and Infectious Diseases 1994, 19: 217-220.
53. Columbo AL, Barchiesi F, McGough DA, Fothergill AW, Rinaldi MG: Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. Journal of Antimicrobial Chemotherapy 1995, 36: 93-100.
54. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG: Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. Journal of Clinical Microbiology 1995, 36: 535-540.
55. Schmalreck AF, Kottmann I, Reiser A, Ruffer U, Scharr E, Vanca E: An evaluation of seven methods of testing in vitro susceptibility of clinical yeast isolates to fluconazole. Mycoses 1995, 38: 359-368.
56. Reynes J, Mallie M, Andre D, Janbon F, Bastide JM: Traitement et prophylaxie secondaire par fluconazole des candidoses oropharyngees des sujets VIH: analyse mycologique des échecs. Pathologie Biologie 1992, 40: 513-517.
57. Hundt W, Hofman H: In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long term treatment with azoles in HIV-infected patients. Infection 1994, 22: 124-130.
58. Plempel M, Berg D, Buchel KH, Abbink D: Test method for antifungal agents; a critical review. Mykosen 1987, 30: 28-37.
59. Galgiani JN, Stevens DA: Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrobial Agents and Chemotherapy 1976, 10: 721-726.
60. Wardle HM, Law D, Moore CB, Mason CM, Denning DW: The in vitro activity of D0870 compared with other azoles against fluconazole resistant Candida spp. Antimicrobial Agents and Chemotherapy 1995, 39: 868-871.
61. Pfaller MA, Bale MJ, Buschelman B, Rhomberg P: Antifungal activity of a new triazole, DO870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata. Diagnostic Microbiology and Infectious Diseases 1994, 19: 75-80.
62. Radetsky M, Wheeler RC, Roe MH, Todd JK: Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. Journal of Clinical Microbiology 1986, 24: 600-606.
63. Hacek DM, Noskin GA, Trakas K, Peterson LR: Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory. Journal of Clinical Microbiology 1995, 337: 1884-1889.
64. Tellier R, Krajden M, Grigoriew GA, Campbell I: Innovative endpoint determination system of antifungal susceptibility testing of yeasts. Antimicrobial Agents and Chemotherapy 1992, 36: 1619-1625.
65. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP: Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 911-915.
66. Wanger A, Mills K, Nelson PW, Rex JH: Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrobial Agents and Chemotherapy 1995, 39: 2520-2522.
67. Johnson EM, Richardson MD, Warnock DW: In vitro resistance to imidazole antifungals in Candida albicans. Journal of Antimicrobial Chemotherapy 1984, 13: 547-558.
68. Oh K, Matsuoka H, Sumita O, Takatori K, Kurata H: Evaluation of antifungal activity of antimycotics by automatic analyzing system. Mycopathologica 1992, 118: 71-81.
69. 3H]glucose incorporation assay for determination of lymphoid-cell mediated inhibition of Candida albicans growth. Journal of Immunological Methods 1986, 92: 73-77.
70. Hughes CE, Bennett RL, Tuna IC, Beggs WH: Activities of fluconazole UK 49858 and ketoconazole against ketoconazole-susceptible and-resistant Candida albicans. Antimicrobial Agents and Chemotherapy 1988, 32: 209-212.
71. Odds FC: Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrobial Agents and Chemotherapy 1982, 22: 763-770.
72. Odds FC, Abbott AB: Relative inhibition factors - a novel approach to the assessment of antifungal antibiotics in vivo. Journal of Antimicrobial Chemotherapy 1984, 13: 31-43.
73. Green L, Petersen B, Steimel L, Haeber P, Current W: Rapid determination of antifungal activity by flow cytometry. Journal of Clinical Microbiology 1994, 32: 1088-1091.
74. Fromtling RA, Galgiani JN, Pfaller MA, Espinel-Ingroff A, Bartizal KF, Bartlett MS, Body BA, Frey C, Hall G, Roberts GD, Nolte FB, Odds FC, Rinaldi MG, Sugar AM, Villareal K: Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrobial Agents and Chemotherapy 1993, 37: 39-45.
75. Law D, Moore CB, Joseph LA, Keaney MGL, Denning DW: High incidence of antifungal drug resistance in Candida tropicalis. International Journal of Antimicrobial Agents 1996, 7: 241-245.
76. Rodriguez-Tudela JL, Martinez-Suarez JV, Dronda F, Laguna F, Chaves F, Valencia E: Correlation of in vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. Journal of Antimicrobial Chemotherapy 1995, 35: 793-804.
77. Baily GG, Perry FM, Denning DW, Mandai BK: Fluconazole resistant candidosis in an HIV cohort. AIDS 1994, 8: 787-792.
78. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz MG, Gallant JE: Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 1996, 173: 219-225.
79. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents and Chemotherapy 1995, 39: 2378-2386.
80. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG: In vitro activity of itraconazole against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 1994, 38: 1530-1533.
81. Valentin A, Le Guennec R, Rodriguez E, Reynes J, Mallie M, Bastide JM: Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model. Antimicrobial Agents and Chemotherapy 1996, 40: 1342-1345.
82. Casals JB: Tablet sensitivity testing of pathogenic fungi. Journal of Clinical Pathology 1979, 32: 719-722.
83. British Society for Antimicrobial Chemotherapy: Working Party Report. Antifungal drug susceptibility testing. Journal of Antimicrobial Chemotherapy 1995, 36: 899-909.
84. Lynch ME, Sobel JD: Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. Journal of Medical and Veterinary Mycology 1994, 32: 267-274.
85. Pfaller MA, Grant C, Morthland V, Rhine-Chalberg J: Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. Journal of Clinical Microbiology 1994, 32: 506-509.
86. Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick V: Correlation between in vitro and in vivo activity of antifungal agents against Candida species. Journal of Infectious Diseases 1994, 170: 384-389.
87. Pfaller MA, Bale MJ, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG, Cooper CR, McGinnis MR: Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing for amphotericin B, fluconazole and flucytosine. Journal of Clinical Microbiology 1995, 33: 1104-1107.
88. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K: Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clinical Infectious Diseases 1994, 19: 684-686.
89. Pfaller MA, Rhine-Chalberg J, Redding SW, Smith J, Farinacci G, Fothergill AW, Rinaldi MG: Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. Journal of Clinical Microbiology 1994, 32: 59-64.
90. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, Kauffman CA: Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment and emergence of fluconazole resistance. American Journal of Medicine 1994, 97: 339-346.
91. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA: Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 1994, 38: 2495-2497.
92. Barchiesi F, Hollis RJ, McGough DA, Scalise G, Rinaldi MG, Pfaller MA: DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clinical Infectious Diseases 1995, 20: 634-640.
93. Bart-Delabesse E, Boiron P, Carlotti A, Dupont B: Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. Journal of Clinical Microbiology 1993, 31: 2933-2937.
94. Dupont B: Resistance trends in oral Candida infections: the clinical challenge. Clinician 1993, 11: 19-22.
95. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. American Journal of Medicine 1996, 100: 617-623.
96. Voss A, Meis JFGM, Hoogkamp-Korstanje JAA: Fluconazole in the management of fungal urinary tract infections. Infection 1994, 22: 247-251.
97. Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New England Journal of Medicine 1995, 333: 474-480.
98. Nelson MR, Fisher M, Cartledge J, Rogers T, Gazzard BG: The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994, 8: 651-654.
99. Odds FC: Resistance of clinically important yeasts to antifungal agents. International Journal of Antimicrobial Agents 1996, 6: 145-147.
100. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL: Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clinical Infectious Diseases 1997, 24: 235-247.
101. Vanden Bossche H, Marichal P, Odds FC: Molecular mechanisms of drug resistance in fungi. Trends in Microbiology 1994, 2: 393-400.
102. Parkinson T, Falconer DJ, Hitchcock CA: Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrobial Agents and Chemotherapy 1995, 39: 1696-1699.
103. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL: Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiology Letters 1995, 131: 337-341.
104. Prasad R, de Wergifosse P, Goffeau A, Balzi E: Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Current Genetics 1995, 27: 320-329.
105. Ben-Yaacov R, Knoller S, Caldwell GA, Becker JM, Koltin Y: Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrobial Agents and Chemotherapy 1994, 38: 648-652.
106. Marichal P, Gorrens J, Coene MC, Le Jeune L, Vanden Bossche H: Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 1995, 38: 111-117.
107. Venkateswarlu K, Denning DW, Kelly SL: Inhibition and interaction of sterol 14a-demethylase of Candida krusei with azole antifungal drugs. Journal of Medical and Veterinary Mycology 1997, 35: 19-25.
108. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL: Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrobial Agents and Chemotherapy 1996, 40: 1382-1386.
109. Kelly SL, Kelly DE: Molecular studies on azole sensitivity in fungi. In: Maresca B, Kobayashi GS, Yamaguchi H (ed): Molecular biology and its application to medical mycology. Springer Verlag, Berlin 1993, p. 199-213.
110. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE: Mode of action and resistance to azole antifungals associated with the formation of 14a-methylergosta-8,24(28)-dien-3β,6a-diol. Biochemical and Biophysical Research Communications 1995, 207: 910-915.
111. Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H: Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 1996, 348: 1523-1524.
112. Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC: Characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy 1992, 36: 2602-2610.
113. Warnock DW, Burke J, Cope NJ, Johnson EM, von Fraunhofer NA, Williams EW: Fluconazole resistance in Candida glabrata. Lancet 1988, ii: 1310.
114. Joseph-Home T, Holloman D, Loeffler RST, Kelly SL: Altered P450 activity associated with direct selection for fungal azole resistance. FEBS Letters 1995, 374: 174-178.
115. Selik RM, Starcher T, Curran JW: Opportunistic diseases reported in AIDS patients: Frequencies, associations, and trends. AIDS 1987, 1: 175-182.
116. Fisher-Hoch SP, Hutwagner L: Opportunistic candidiasis: an epidemic of the 1980s. Clinical Infectious Diseases 1995, 21: 897-904.
117. Beck-Sague CM, Jarvis WR, National Nosocomial Infections Surveillance System: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. Journal of Infectious Diseases 1993, 167: 1247-1251.
118. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Cunagan WC: Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clinical Infectious Diseases 1992, 15: 414-421.
119. Komshian SV, Uwaydah AK, Sobel JD, Crane LR: Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics and evaluation of factors including outcome. Reviews of Infectious Diseases 1989, 11: 379-390.
120. Price MF, LaRocco MT, Gentry LO: Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5 year period. Antimicrobial Agents and Chemotherapy 1994, 38: 1422-1424.
121. Galgiani JN: Susceptibility of Candida albicans and other yeasts to fluconazole: Relation between in vitro and in vivo studies. Reviews of Infectious Diseases 1990, 12, Supplement 1: 272-275.
122. Boken DJ, Swindells S, Rinaldi MG: Fluconazole-resistant Candida albicans. Clinical Infectious Diseases 1993, 17: 1018-1021.
123. Plettenburg A, Stoehr A, Hoffken G: Fluconazole therapy of oral candidiasis in HIV infected patients: results of a multicentre study. Infection 1994, 22: 118-123.
124. Redding S, Smith J, Faranacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J, Pfaller M: Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clinical Infectious Diseases 1994, 18: 240-242.
125. Boerlin P, Boerlin-Petzold F, Goudet J, Durussel C, Pagani JL, Chave JP, Bille J: Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting. Journal of Clinical Microbiology 1996, 34: 1235-1248.
126. Lischewski A, Ruhnke M, Tennagen I, Schonian G, Morschhauser J, Hacker J: Molecular epidemiology of Candida isolates from AIDS patients showing different fluconazole resistance patterns profiles. Journal of Clinical Microbiology 1995, 33: 769-771.
127. Espinel-Ingroff A, Quart A, Steele-Moore L, Metchera I, Buck GA, Bruzzese BL, Reich D: Molecular karyotyping of multiple yeast species isolated from nine patients with AIDS during prolonged fluconazole therapy. Journal of Medical and Veterinary Mycology 1996, 34: 111-116.
128. McCullough MJ, Ross BC, Dwyer BD, Reader PC: Genotype and phenotype of oral Candida albicans from patients infected with the human immunodeficiency virus. Microbiology 1993, 140: 1195-1202.
129. Powderly WG, Robinson K, Keath EJ: Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus positive patients: evidence for two patterns of recurrence. Journal of Infectious Diseases 1993, 168: 463-466.
130. Goff DA, Koletar SL, Buesching WG, Barnishan J, Fass RJ: Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clinical Infectious Diseases 1995, 20: 77-83.
131. Berenguer J, Fernandez-Baca V, Sanchez R, Bouza E: In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 363-365.
132. Heald AE, Cox GM, Schell WA, Bartlett JA, Perfect JR: Oropharyngeal yeast flora and fluconazole resistance in HIV infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 1996, 10: 263-268.
133. Dronda F, Alonso-Sanz M, Laguna F, Chaves F, Martinez-Suarez JV, Rodriguez-Tudela JL, Gonzalez-Lopez A, Valencia E: Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans strains in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1996, 15: 446-452.
134. Tom W, Aaron JS: Oesophageal ulcers caused by Torulopsis glabrata in a patient with acquired immune deficiency syndrome. American Journal of Gastroenterology 1987, 82: 766-768.
135. Just-Nubling G, Gentschew, B, Dohle M, Bottinger C, Helm EB, Stille W: Fluconazole in the treatment of oropharyngeal candidosis in HIV positive patients. Mycoses 1990, 33: 435-440.
136. Spinillo A, Michelone G, Cavanna C, Colonna L, Capuzzo E, Nicola S: Clinical and microbiological characteristics of symptomatic vulvovaginal candidiasis in HIV seropositive women. Genitourinary Medicine 1994, 70: 268-272.
137. Baily GG, Moore CB, De Wit S, Denning DW: Candida inconspicua, another fluconazole resistant Candida species in HIV patients. Clinical Infectious Diseases 1997, in press.
138. Hood SV, Moore CB, Denning DW: The isolation of Candida norvegensis from clinical specimens: four case reports. Clinical Infectious Diseases 1996, 23: 1185-1187.
139. Reynes J, Mallie M, Azay J, Janbon F, Bastide JM, Bertrand A: Echecs cliniques du fluconazole dans la prophylaxie a long terme des candidoses oesophagiennes chez des patients ayant une immunodepression sévère liée au VIH. Bulletin of the French Society of Medical Mycology 1990, 19: 155-157.
140. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 1991, 325: 1274-1277.
141. Guttierrez F: An analysis of the trends in the use of antifungal drugs and fungal isolates in a UK university hospital. Journal of Hospital Infection 1995, 31: 149-151.
142. Coste T, Barale T, Reboux G, Talon D, Cahn JY: Prophylaxie antifongique par fluconazole: son influence sur l'augmentation de la fréquence d'isolement de Candida glabrata. Bulletin of the French Society for Medical Mycology 1990, 19: 151-154.
143. Kunovà A, Trupl J, Dluholucký S, Galovà G, Krčméry V: Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. Clinical Infectious Diseases 1995, 21: 226-227.
144. de Pauw BE, Raemaekers JMM, Donnelly JP, Kullberg BJ, Meis JFGM: An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of Hematology 1995, 70: 83-87.
145. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheid WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD, for the Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 1994, 331: 1325-1330.
146. Nguyen MH, Peacock JE, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL: Therapeutic approaches in patients with candidemia. Evaluation of a multicenter, prospective, observational study. Archives of Internal Medicine 1995, 155: 2429-2435.
147. British Society for Medical Mycology Subcommittee on Diagnostic Mycology: Management of genital candidiasis. British Medical Journal 1995, 310: 1241-1244.
148. Sobel JD, Vazquez JA: Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clinical Infectious Diseases 1996, 22: 726-727.
149. Leen CLS, Dunbar EM, Ellis ME, Mandal BK: Once weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS related complex: a double blind placebo controlled study. Journal of Infection 1990, 21: 55-60.
150. Vuffray A, Durussel C, Boerlin C, Boerlin-Petzold F, Bille J, Glauser MP, Chave JP: Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994, 8: 708-709.
151. British Society for Antimicrobial Chemotherapy Working Party: Antifungal chemotherapy in patients with acquired immunodeficiency syndrome. Lancet 1992,
152. Cartledge JD, Midgley J, Youle M, Gazzard BG: Itraconazole cyclodextrin solution - effective treatment for HIV related candidosis unresponsive to other azole therapy. Journal of Antimicrobial Chemotherapy 1994, 33: 1071-1073.
153. Dewsnup DH, Stevens DA: Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. Journal of Medical and Veterinary Mycology 1994, 32: 389-393.
154. Galgiani JN, Lewis ML: In vitro studies of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans and other pathogenic yeasts. Antimicrobial Agents and Chemotherapy 1997, 41: 180-183.
155. Wardle H, Law D, Denning DW: In vitro activity of pradimicin against fluconazole resistant Candida spp. Antimicrobial Agents and Chemotherapy 1996, 40: 2229-2231.
156. Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskobitz BL, Mechlinkski W, Van de Velde V: Food interaction and steady state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrobial Agents and Chemotherapy 1993, 37: 778-784.
157. Slum RA, D'Andrea DT, Florentino BM, Wilton JH, Hilligross DM, Gardner MJ, Henry EB, Goldstein H, Schentag JJ: Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Annals of Internal Medicine 1991, 114: 755-757.
158. Tucker RM, Hanson LH, Denning DW, Rinaldi M, Graybill JR, Sharkey PK, Stevens DA: Interaction of azoles with rifampin, phenytoin, and carbemazepine: in vitro and clinical observations. Clinical Infectious Diseases 1992, 14: 165-174.
159. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A: Treatment of Candida albicans fungaemia with fluconazole. Journal of Infection 1993, 26: 133-146.
160. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, Pizzo PA, Walsh TJ: Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes. Clinical Infectious Diseases 1992, 14: 875-883.
161. Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE, Washburn RG, for the NIAID Mycoses Study Group and the Candidemia Study Group: Intravascular catheter exchange and duration of candidemia. Clinical Infectious Diseases 1995, 21: 994-996.
162. White A, Goetz MB: Azole-resistant Candida albicans. Report of two cases of resistance to fluconazole and review. Clinical Infectious Diseases 1994, 19: 687-692.
163. Weese-Mayer DE, Wheeler Fondriest D, Brouillette RT, Shulman ST: Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatric Infectious Diseases Journal 1987, 6: 190-196.